MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 577463 | Name: Mitiglinide calcium hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mitiglinide calcium hydrate is a potassium channel blocker.

Chemical Structure

Mitiglinide calcium hydrate
Mitiglinide calcium hydrate
CAS#207844-01-7

Theoretical Analysis

MedKoo Cat#: 577463

Name: Mitiglinide calcium hydrate

CAS#: 207844-01-7

Chemical Formula: C38H52CaN2O8

Exact Mass: 704.3350

Molecular Weight: 704.92

Elemental Analysis: C, 64.75; H, 7.44; Ca, 5.69; N, 3.97; O, 18.16

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Mitiglinide calcium hydrate
IUPAC/Chemical Name
(S)-2-Benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)butyric acid calcium salt dihydrate
InChi Key
QEVLNUAVAONTEW-UZYHXJQGSA-L
InChi Code
InChI=1S/2C19H25NO3.Ca.2H2O/c2*21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14;;;/h2*1-3,6-7,15-17H,4-5,8-13H2,(H,22,23);;2*1H2/q;;+2;;/p-2/t2*15-,16+,17-;;;/m00.../s1
SMILES Code
O.O.[Ca+2].[O-]C(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc3ccccc3.[O-]C(=O)[C@H](CC(=O)N4C[C@H]5CCCC[C@H]5C4)Cc6ccccc6
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 704.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Son JW, Lee IK, Woo JT, Baik SH, Jang HC, Lee KW, Cha BS, Sung YA, Park TS, Yoo SJ, Yoon KH. A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes. Endocr J. 2015;62(12):1049-57. doi: 10.1507/endocrj.EJ15-0325. Epub 2015 Sep 25. PubMed PMID: 26411328. 2: Takeshita Y, Takamura T, Kita Y, Takazakura A, Kato K, Isobe Y, Kaneko S. Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study. BMJ Open Diabetes Res Care. 2015 Aug 28;3(1):e000122. doi: 10.1136/bmjdrc-2015-000122. eCollection 2015. PubMed PMID: 26336611; PubMed Central PMCID: PMC4553908. 3: Al Azzam KM, Muhammad E. Host-guest Inclusion Complexes between Mitiglinide and the Naturally Occurring Cyclodextrins α, β, and γ: A Theoretical Approach. Adv Pharm Bull. 2015 Jun;5(2):289-91. doi: 10.15171/apb.2015.040. Epub 2015 Jun 1. PubMed PMID: 26236670; PubMed Central PMCID: PMC4517090. 4: Tani S, Nagao K, Hirayama A. Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study. Drug Res (Stuttg). 2016 Feb;66(2):94-9. doi: 10.1055/s-0035-1549993. Epub 2015 May 26. PubMed PMID: 26011816. 5: Baek JH, Jin SM, Kaku K, Jung JA, Kim JR, Ko JW, Kim MJ, Lee SY, Huh WS, Kim JH. Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment. Expert Opin Pharmacother. 2015 Jun;16(8):1127-36. doi: 10.1517/14656566.2015.1035646. Epub 2015 Apr 16. PubMed PMID: 25881690. 6: Murakami T, Nambu T, Kato T, Matsuda Y, Yonemitsu S, Muro S, Oki S. Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin. Tohoku J Exp Med. 2015;235(4):255-60. doi: 10.1620/tjem.235.255. PubMed PMID: 25810423. 7: Ando K, Nishimura R, Seo C, Tsujino D, Sakamoto M, Utsunomiya K. Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study. Expert Opin Pharmacother. 2014 Dec;15(17):2479-85. doi: 10.1517/14656566.2014.970531. Epub 2014 Oct 20. PubMed PMID: 25327311. 8: Akahane K, Inoue T, Yokoyama A, Yaguchi A, Ojima K, Kiguchi S, Maruyama K, Kobayashi M, Mori Y. Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats. Drug Res (Stuttg). 2015 Aug;65(8):416-21. doi: 10.1055/s-0034-1387719. Epub 2014 Sep 4. PubMed PMID: 25188606. 9: Ono Y, Kamoshima H, Nakamura A, Nomoto H. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination. Expert Opin Pharmacother. 2014 Sep;15(13):1785-95. doi: 10.1517/14656566.2014.939070. Epub 2014 Jul 21. PubMed PMID: 25046055. 10: Osonoi T, Saito M, Tamasawa A, Ishida H, Osonoi Y. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study. Expert Opin Pharmacother. 2014 Jul;15(10):1325-35. doi: 10.1517/14656566.2014.920323. Epub 2014 May 27. Erratum in: Expert Opin Pharmacother. 2014 Aug;15(11):1637. PubMed PMID: 24866329. 11: Kimura H, Matsuda H, Fujimoto H, Arimitsu K, Toyoda K, Mukai E, Nakamura H, Ogawa Y, Takagi M, Ono M, Inagaki N, Saji H. Synthesis and evaluation of 18F-labeled mitiglinide derivatives as positron emission tomography tracers for β-cell imaging. Bioorg Med Chem. 2014 Jul 1;22(13):3270-8. doi: 10.1016/j.bmc.2014.04.059. Epub 2014 May 6. PubMed PMID: 24842616. 12: Ihana N, Tsujimoto T, Yamamoto-Honda R, Kishimoto M, Kajio H, Noto H, Kakei M, Noda M. Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study. Diabetol Metab Syndr. 2014 Mar 31;6:48. doi: 10.1186/1758-5996-6-48. eCollection 2014. PubMed PMID: 24684803; PubMed Central PMCID: PMC4025538. 13: Kaku K, Inagaki N, Kobayashi N. Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy. Diabetes Ther. 2014 Jun;5(1):97-111. doi: 10.1007/s13300-014-0051-5. Epub 2014 Feb 1. PubMed PMID: 24488695; PubMed Central PMCID: PMC4065298. 14: Zeng Y, Xie X, Duan J, Zhou T, Zhang Y, Yang M, Xu F. Perturbation of mitiglinide metabolism by chronic unpredicted mild stress in rats. Sci Rep. 2014 Jan 21;4:3794. doi: 10.1038/srep03794. PubMed PMID: 24445843; PubMed Central PMCID: PMC3896903. 15: Ono Y, Nakamura A, Cho KY, Nomoto H. The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2014 Feb;15(3):311-24. doi: 10.1517/14656566.2014.868437. Epub 2013 Dec 13. PubMed PMID: 24328511. 16: Jung JA, Kaku K, Kim JH, Kim JR, Ko JW, Lee SY, Huh W. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus. Adv Ther. 2013 Nov;30(11):1018-29. doi: 10.1007/s12325-013-0072-x. Epub 2013 Nov 19. Erratum in: Adv Ther. 2014 Jan;31(1):149. PubMed PMID: 24249434. 17: Ohta A, Ohshige T, Sakai K, Nakamura Y, Tenjin A, Tsukiyama S, Terashima Y, Matsubara F, Kawata T, Nagai Y, Tanaka Y. Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes. Expert Opin Pharmacother. 2013 Dec;14(17):2315-22. doi: 10.1517/14656566.2013.842554. Epub 2013 Sep 30. PubMed PMID: 24079645. 18: Konya H, Katsuno T, Tsunoda T, Yano Y, Kamitani M, Miuchi M, Hamaguchi T, Miyagawa J, Namba M. Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2013 Sep 2;6:317-25. doi: 10.2147/DMSO.S36046. Review. PubMed PMID: 24039439; PubMed Central PMCID: PMC3769413. 19: Phillippe HM, Wargo KA. Mitiglinide for type 2 diabetes treatment. Expert Opin Pharmacother. 2013 Oct;14(15):2133-44. doi: 10.1517/14656566.2013.834048. Epub 2013 Aug 30. Review. PubMed PMID: 23992284. 20: Kodani N, Saisho Y, Tanaka K, Kawai T, Itoh H. Effects of mitiglinide, a short-acting insulin secretagogue, on daily glycemic variability and oxidative stress markers in Japanese patients with type 2 diabetes mellitus. Clin Drug Investig. 2013 Aug;33(8):563-70. PubMed PMID: 23797928.

View History

Mitoflaxone sodium

Mitoflaxone sodium